EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

L-Asparaginase Exposure and Immune Fitness in Pediatric Acute Lymphoblastic Leukemia: A Critical Evidence Appraisal for Immunotherapy Integration

Di Yao, Xiaoyan Lin, Chunming Jiang

Cancer Treatment and Research Communications · 2026-11 · 101538

DOI: 10.1016/j.ctarc.2026.101538 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2026-11. Verfasst von Di Yao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China. Electronic ad…. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

L-asparaginase (L-ASP) is indispensable in pediatric acute lymphoblastic leukemia (ALL), but circulating and marrow-resident immune cells encounter the same systemic amino-acid perturbation as leukemic blasts. Whether this exposure modifies the fitness of cells required for immunotherapy remains unresolved. This critical narrative review evaluates L-ASP and amino-acid-restriction evidence across T cells, natural killer cells, B cells, macrophages, and the bone-marrow niche, and relates it to blinatumomab, chimeric antigen receptor T-cell therapy, and checkpoint blockade. We assess intervention directness, clinical relevance, and study quality separately. T-cell studies show that asparagine supports early activation, whereas selected activated CD8⁺ states can mount an activating transcription factor 4 (ATF4)-dependent nuclear factor erythroid 2-related factor 2 (NRF2) response under defined restriction conditions. Direct in-vitro asparaginase studies report differing effects on human natural killer-cell killing and should be distinguished from glutamine withdrawal or intracellular glutaminase inhibition; direct enzyme-exposure studies also identify B-cell and macrophage effects in non-pediatric-ALL models, while local marrow effects remain uncertain. Clinical regimens establish that L-ASP and immunotherapies can be used within the same treatment programme, but they do not define a metabolic washout interval. We therefore distinguish serum enzyme activity, biochemical substrate recovery, and functional immune recovery. Prospective studies should link these measures to partner-specific cellular, manufacturing, and clinical endpoints. Current evidence supports testable compatibility hypotheses, not fixed scheduling rules.

Schlagwörter

Stichwörter der Autor:innen

ImmunometabolismImmunopharmacologyImmunotherapy sequencingL-asparaginasePediatric acute lymphoblastic leukemia

Autor:innen und Institutionen

  • Department of Pediatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China. Electronic address: 872300641@qq.com.
  • Department of Pediatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China. Electronic address: linxiaoyan8256@163.com.
  • Department of Pediatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China. Electronic address: jiangchunming@hospital.westlake.edu.cn.

Zitieren

APA

Yao, D., Lin, X., & Jiang, C. (2026). L-Asparaginase Exposure and Immune Fitness in Pediatric Acute Lymphoblastic Leukemia: A Critical Evidence Appraisal for Immunotherapy Integration. Cancer Treatment and Research Communications, 101538. https://doi.org/10.1016/j.ctarc.2026.101538

Vancouver

Yao D, Lin X, Jiang C. L-Asparaginase Exposure and Immune Fitness in Pediatric Acute Lymphoblastic Leukemia: A Critical Evidence Appraisal for Immunotherapy Integration. Cancer Treatment and Research Communications. 2026:101538. doi:10.1016/j.ctarc.2026.101538

BibTeX
@article{Yao2026,
  author = {Yao, Di and Lin, Xiaoyan and Jiang, Chunming},
  title = {L-Asparaginase Exposure and Immune Fitness in Pediatric Acute Lymphoblastic Leukemia: A Critical Evidence Appraisal for Immunotherapy Integration},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  pages = {101538},
  doi = {10.1016/j.ctarc.2026.101538}
}
Kostenlos starten →